Transforming Tumor Research: Engineering MHCs as Versatile Reagents

By Yujiao Zhang

ManHee Suh's Talk @ CAR-TCR Summit

We are delighted to share with you our experience at the 8th CAR-TCR Summit in Boston as part of the KACTUS team. Our Chief Technology Officer, ManHee Suh, presented his work on "Transforming Tumor Research: Engineering Major Histocompatibility Complexes (MHCs) as Versatile Reagents," which received a positive response from the audience.

We are excited to share the remarkable results from our in-house data with you. If you're interested in our research, we encourage you to fill out the form and receive more information on test samples, along with a full copy of the poster. We understand the importance of this work, and we're here to support you every step of the way.

Preview of In-House Data

When dealing with solid tumors lacking specific biomarkers, the effectiveness of adoptive T cell therapy using CAR-T treatments is limited. The absence of dependable, multifaceted MHC reagents has been a hindrance in the research and development of treatments for solid tumors. To tackle this challenge, we have engineered MHC molecules in several formats with diverse applications. These improved MHC molecules have the potential to facilitate solid tumor research and development.

SCT (Single-Chain Trimer) MHC for High Peptide Occupancy


Figure 1. Structural analyses of over 200 TCR-peptide MHC I/II complexes reveal that the linkers in SCT MHC are not in close proximity to the TCR-peptide-MHC interfaces.

Request More Information

If you're interested in learning more about our research and accessing the full copy of ManHee Suh's poster, simply submit the form below. By doing so, you'll also receive information on how to obtain test samples for further exploration.